inHEART Raises $4.2 Million to Improve Treatments for Cardiac Arrhythmias With Continued Development of Artificial Intelligence

inHEART, providing a cloud-based medical image analysis solution for cardiac interventions on patients with arrhythmias, has closed a round of EUR 3.7 million led by Elaia. These funds will be used to accelerate commercial development in Europe, access the US market, and advance its technology leadership with continued development of AI and numerical simulations of cardiac electrical activity. "We are very happy to have Elaia joining inHEART in this adventure not only for its financial support but also for the dynamism and the expertise of its team in developing startups in healthcare. Elaia and inHEART share the same ambition to create a major player in cardiac electrophysiology, a EUR 5 billion market with healthcare giants such as Johnson & Johnson, Abbott, Boston Scientific or Medtronic," said Jean-Marc Peyrat, CEO and co-founder of inHEART. Heart rhythm disorders, notably as the cause of sudden cardiac death, is a major cause of morbidity in the world. Current treatment solutions for patients with arrhythmias are not optimal whether considering drugs, implantable devices or even catheter ablation procedures that are lengthy, complex and expensive. For instance, a repeat procedure is needed in 40% of patients with ventricular arrhythmias due to recurrence.